CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, will announce new clinical findings for ANKTIVA ® (nogapendekin alfa inbakicept-pmln) in ...
3D modeling for robotic prostatectomy Cost comparison of checkpoint inhibitors in high-risk bladder cancer AI-generated prostate cancer mapping A wearable optical system for bladder monitoring after ...
ODAC unanimously opposed Talzenna/Xtandi for non-HRR-mutant mCRPC due to increased toxicity and undefined efficacy in non-HRR-mutated patients. UGN-102 for recurrent NMIBC faced a narrow vote against ...
Cancer diagnoses traditionally require invasive or labor-intensive procedures such as tissue biopsies. Researchers at the Ludwig-Maximilians-Universität München (LMU) have now reported on a method ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback